about
Genomics and biological activity of neutrophil gelatinase-associated lipocalin in several clinical settingsA lipocalin-derived Peptide modulating fibroblasts and extracellular matrix proteins.A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis.Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cellsRoles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.Lipocalin-2 Acts as a Neuroinflammatogen in Lipopolysaccharide-injected Mice.Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias.Lipocalin-2 deficiency attenuates neuroinflammation and brain injury after transient middle cerebral artery occlusion in miceTranscription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinomaLipocalin 2 is essential for chronic kidney disease progression in mice and humans.The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancerExtended exposure to dietary melatonin reduces tumor number and size in aged male mice.Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progressionLipocalin 2 deficiency alters estradiol production and estrogen receptor signaling in female miceEpigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.Enhancement of ionizing radiation response by histamine in vitro and in vivo in human breast cancer.ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast CancerLipocalin 2 is a novel regulator of angiogenesis in human breast cancer.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineLipopolysaccharide-induced inflammation or unilateral ureteral obstruction yielded multiple types of glycosylated Lipocalin 2Overexpression of lipocalin 2 in human cervical cancer enhances tumor invasion.Effects of ectopic expression of NGAL on doxorubicin sensitivity.The Ligands of Neutrophil Gelatinase-Associated LipocalinAdipocytes promote malignant growth of breast tumours with monocarboxylate transporter 2 expression via β-hydroxybutyrate.Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockadeRelationships of lipocalin 2 with breast tumorigenesis and metastasis.Lipocalin 2 prevents oral cancer metastasis through carbonic anhydrase IX inhibition and is associated with favourable prognosis.Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis.Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.Higher lipocalin 2 expression may represent an independent favorable prognostic factor in cytogenetically normal acute myeloid leukemia.Lipocalin-2 induces apoptosis in human hepatocellular carcinoma cells through activation of mitochondria pathways.Hypothalamic food intake regulation in a cancer-cachectic mouse model.Lack of adrenomedullin in mouse endothelial cells results in defective angiogenesis, enhanced vascular permeability, less metastasis, and more brain damage.Prospects for treating osteoarthritis: enzyme-protein interactions regulating matrix metalloproteinase activity.Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial CancerTreatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene.Implications of lipocalin 2 expression in acute myeloid leukemia.Revisiting Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Cancer: Saint or Sinner?
P2860
Q27011425-F6B6E7C4-594D-44C6-B4E9-BE3774013275Q30155283-1942041C-1E66-4F31-8AFB-D2841AF710F9Q30384899-B24FE501-E547-487F-A1C6-8F1106245C59Q33651509-5D7323F3-0489-4416-BD41-CC9635B25F05Q33688934-AC496ECC-A3AA-422F-B350-A4A0D302F6BEQ33787342-0FD70350-61B8-44AA-B0A3-B6CFFC6B5FE6Q33820258-3E87D4D9-AEFF-4662-9CBB-4430617E27ABQ34018660-E3FE6F6E-5C92-4D82-AA64-D67B4194D6B4Q34181413-5F883D69-8DF2-448F-BE69-C386F9D3EB0AQ34245315-3E34FFCB-F337-465B-9662-15024F4101BCQ34284339-6A853CD0-B5BF-4D11-9430-DEA8B72202D1Q34388391-8CD80033-9FF3-41C8-A8EC-340B87F63783Q35126653-A0D90422-3DE1-4947-A429-4ABEAC3DE2B2Q35762647-A9055A63-B951-4077-A49E-EF24B50B8040Q35843206-AF787C1B-BBA1-4AFD-9676-E3313DED2481Q36020915-87A1C53B-3524-43B6-B04E-54171DE8666EQ36213171-C4B0EF2A-F628-4174-B5C2-0AA2ABBD4812Q36372319-D7A5B5D7-E984-4EB8-9EC0-878514AF76DFQ36482942-68E0DABA-836E-47B0-B521-82FBEAD4D9F5Q36556350-648EC845-BA55-4C21-8970-BF1148288F7BQ36655357-91A2CC7D-DC08-4F46-99A6-443441CEDF1EQ36998174-70B88013-F7DC-4454-9DA1-5C2E641852D0Q37031268-4A054CA7-FFE3-4BE7-8AD7-B8EC367A55E6Q37238644-D16D94BA-F2FB-4695-835A-91AE4032FCB7Q37704618-38E07A36-56BE-47CB-B6F3-38D9B12BA860Q37714248-E100B008-4484-4D18-97CF-6C70D4EE7E11Q37790657-D5B64B2D-068D-49B8-93B8-3049B14F162DQ38769524-FD84B4DC-31BB-475D-A400-3DBED28BD659Q38781389-12E9AD1C-24D3-4038-8D5B-0ED346F05011Q38904753-6B68A6D8-6B70-4650-BB1A-D193F5D972D5Q39245039-68D8E17B-57BF-42B2-9C8B-BD3702E03A58Q39329655-A6E9FCE3-31ED-4816-A06C-4E2BB9DF3DEDQ40580808-ECC65B5C-B93F-47DC-BC89-75EE0C82C986Q41117906-2F0A166F-416C-4AEA-9001-CE87872F687DQ42253266-A06F69B8-539C-42AB-BBE7-C095587B57C2Q42706072-AB7868F6-F5AB-436D-8110-B96CFBA04C60Q45358201-5CF44A34-7449-469C-B67A-962087C032F3Q45779796-C2FFAD26-C6FE-45E4-8C94-2E5C70BB7063Q58723325-DBBE11C3-D552-4F6B-BD54-CDDE482B7908
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Lipocalin 2: a multifaceted modulator of human cancer.
@ast
Lipocalin 2: a multifaceted modulator of human cancer.
@en
type
label
Lipocalin 2: a multifaceted modulator of human cancer.
@ast
Lipocalin 2: a multifaceted modulator of human cancer.
@en
prefLabel
Lipocalin 2: a multifaceted modulator of human cancer.
@ast
Lipocalin 2: a multifaceted modulator of human cancer.
@en
P2860
P356
P1433
P1476
Lipocalin 2: a multifaceted modulator of human cancer.
@en
P2093
Jiang Yang
Marsha A Moses
P2860
P304
P356
10.4161/CC.8.15.9224
P577
2009-08-08T00:00:00Z